Rasagiline is administered orally, at a dose of 1 mg once daily with or without levodopa. It may be taken with or without food.
Patients with Hepatic Impairment: Rasagiline use in patients with severe hepatic impairment is contraindicated. Rasagiline use in patients with moderate hepatic impairment should be avoided. Caution should be used when initiating treatment with rasagiline in patients with mild hepatic impairment. In case patients progress from mild to moderate hepatic impairment, rasagiline should be stopped.
Patients with Renal Impairment: No change in dose is required for renal impairment.
Elderly: No change in dose is required for elderly patients.